Form 8-K - Current report:
SEC Accession No. 0001651308-25-000029
Filing Date
2025-02-27
Accepted
2025-02-27 06:04:40
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20250227.htm   iXBRL 8-K 32089
2 EX-99.1 exhibit991-q42024earningsr.htm EX-99.1 287333
6 bgnenewlogo2.jpg GRAPHIC 16225
  Complete submission text file 0001651308-25-000029.txt   496972

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20250227.xsd EX-101.SCH 1867
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20250227_lab.xml EX-101.LAB 22720
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20250227_pre.xml EX-101.PRE 13107
17 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20250227_htm.xml XML 3005
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 25672587
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)